StockWire X
Get Free Alerts
StockWire X

Imugene Wins an ASH Poster Slot to Show Its Azer-Cel Lymphoma Data [VIDEO]

Video thumbnail
Imugene Ltd
Company Hub
Market Impact
6/10

Imugene's blood cancer therapy azer-cel will be shown as a poster at the American Society of Hematology meeting in New Orleans on 13 December 2026, in this Imugene azer-cel ASH poster presentation update.

By Josua Ferreira -

Key Takeaways

  • Imugene will show its azer-cel Phase 1b data as a poster at the American Society of Hematology meeting in New Orleans on 13 December 2026.
  • The abstract looks at azer-cel combined with BTK inhibitors in patients with relapsed blood cancers, after earlier treatment stopped working.
  • The poster follows an oral slot at ASCO, where azer-cel was picked from more than 8,500 submitted abstracts.
  • Earlier results cite a 75% combined response rate across 55 Phase 1b patients, with responses seen after prior BTK inhibitor treatment.
  • The announcement adds no new data, and it describes the poster mainly as a chance to be seen by international blood cancer experts.
This is a special feature video produced for our partner.
Topic Hubs
Biotech & Health Biotechnology Healthcare Investment Life Sciences Pharmaceutical Research
Most Popular
Categories

You May Also Like

Breaking ASX Alerts Direct to Your Inbox

Join +20,000 subscribers receiving alerts.

Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.

  • Breaking ASX announcements delivered within minutes
  • Alerts delivered with expert analysis
  • Optional text alert for subscribers
  • No spam policy, unsubscribe any time
News
ASX Stock News
ASX Videos
Trending Topics▾
Capital MarketsRenewable EnergyMedical ImagingPortfolio ManagementASX 200ForexAll OrdinariesInterest RatesInflationAll Hub Pages
Analysis
Education
Free Alerts

About the Publisher

StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.

Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.

Use of Technology

We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.

While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.

Feedback and Accuracy

We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.

Editorial Standards

Disclaimer

StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).

StockWire X Pty Ltd (CAR No. 001 322 642) is a Corporate Authorised Representative of ShareX Pty Ltd (AFSL No. 519872), regulated by the Australian Securities and Investments Commission (ASIC). StockWire X is authorised to provide general financial product advice in relation to basic deposit products, securities, and managed investment schemes.

Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.

StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.

Disclosure

StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.

If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.

Disclaimer